MERCK Kommanditgesellschaft auf Aktien

MRKGermany

43 filed reports · 296 financial concepts · 32 earnings calls

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

€21.1B

FY2025 · to Dec 31, 2025

down −0.3% vs €21.2B

Annual report

Net income

€2.61B

FY2025 · to Dec 31, 2025

down −6.1% vs €2.78B

Annual report

Operating income

€734M

FY2025 · to Dec 31, 2025

up +173% vs €269M

Annual report

Latest quarter

Revenue

€5.13B

Q1 FY2026 · to Mar 31, 2026

down −2.8% vs €5.28B

Q1 report

Net income

—

Operating income

€188M

Q1 FY2026 · to Mar 31, 2026

up +327% vs €44M

Q1 report

Filed reports

43 reports · Mar 2016 to Jun 2026

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Q1Bundesanzeiger141,332Mar 2016 to Mar 2026
Half YearBundesanzeiger111,736Jun 2016 to Jun 2026
Q3Bundesanzeiger101,377Sep 2016 to Sep 2025
AnnualBundesanzeiger8611Dec 2021 to Dec 2025

Documents

PeriodTypePeriod endPublishedFactsSource
FY2026 Q2half year2026-06-302026-06-3025Open
FY2026 Q1q12026-03-312026-03-3117Open
FY2026 Q1q12026-03-312026-03-3182Open
FY2026 Q1q12026-03-312026-03-3168Open
FY2025annual2025-12-312025-12-3110Open
FY2025annual2025-12-312025-12-31116Open
FY2025 Q3q32025-09-302025-09-30146Open
FY2025 Q2half year2025-06-302025-06-30225Open
FY2025 Q1q12025-03-312025-03-31114Open
FY2024annual2024-12-312024-12-31101Open
FY2024annual2024-12-312024-12-316Open
FY2024 Q3q32024-09-302024-09-30151Open

Financial data

296 concepts · 5,056 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

IFRS223 concepts · 3,926 facts · Dec 2015 to Jun 2026

  • Changes recognized in equity94 · Mar 2016 to Mar 2026
  • Tax effect66 · Mar 2016 to Mar 2026
  • Profit after tax63 · Mar 2016 to Jun 2026
  • Operating result (EBIT)¹61 · Mar 2016 to Mar 2026
  • Cost of Revenue57 · Mar 2016 to Mar 2026
  • Gross Profit57 · Mar 2016 to Mar 2026
  • Administration expenses55 · Mar 2016 to Mar 2026
  • Revenue55 · Mar 2016 to Mar 2026
  • Income Tax Expense (Benefit)53 · Mar 2016 to Mar 2026
  • Fair value adjustments52 · Mar 2016 to Mar 2026
  • Marketing and selling expenses52 · Mar 2016 to Mar 2026
  • Pretax Income51 · Mar 2016 to Mar 2026
  • Research and development costs50 · Mar 2016 to Mar 2026
  • Interest Expense48 · Mar 2019 to Mar 2026
  • Financial result44 · Mar 2016 to Mar 2026
  • EPS (Diluted)43 · Mar 2016 to Mar 2026
  • Other operating expenses43 · Mar 2016 to Mar 2026
  • Other operating income43 · Mar 2016 to Mar 2026
  • EPS (Basic)41 · Mar 2016 to Dec 2025
  • Reclassification to profit or loss40 · Jun 2016 to Mar 2026
  • Changes in other assets and liabilities37 · Mar 2016 to Mar 2026
  • Changes in provisions36 · Mar 2016 to Mar 2026
  • Other comprehensive income35 · Mar 2016 to Mar 2026
  • Comprehensive income34 · Mar 2016 to Mar 2026

Segment30 concepts · 683 facts · Mar 2016 to Jun 2026

  • Revenue94 · Mar 2016 to Jun 2026
  • Life Science77 · Mar 2016 to Mar 2026
  • Operating result (EBIT)²54 · Mar 2016 to Mar 2026
  • Depreciation & Amortization52 · Mar 2016 to Mar 2026
  • EBITDA²50 · Mar 2016 to Jun 2025
  • Investments in intangible assets⁴37 · Mar 2016 to Jun 2025
  • Business free cash flow35 · Mar 2016 to Sep 2019
  • EBITDA pre exceptionals (Segment result)34 · Mar 2016 to Jun 2019
  • Investments in property, plant and equipment⁴34 · Mar 2016 to Jun 2025
  • Exceptionals22 · Mar 2016 to Sep 2017
  • Operating Cash Flow22 · Mar 2016 to Jun 2019
  • EBITDA margin pre exceptionals (% of net sales)20 · Mar 2016 to Sep 2017
  • EBITDA pre (Segment result)²20 · Mar 2021 to Jun 2026
  • Performance Materials20 · Mar 2016 to Jun 2019
  • Adjustments²18 · Mar 2021 to Jun 2025
  • Liabilities by business sector³17 · Jun 2018 to Jun 2025
  • Net operating assets¹15 · Mar 2016 to Sep 2017
  • Intersegment sales13 · Mar 2019 to Jun 2025
  • Adjustments312 · Jun 2018 to Jun 2019
  • Impairment losses³11 · Jun 2016 to Jun 2025
  • Non-cash changes in provisions⁵6 · Mar 2021 to Jun 2025
  • Reversals of impairment losses6 · Jun 2016 to Mar 2021
  • Corporate and Other5 · Mar 2021 to Sep 2022
  • share of Group sales attributable to the Healthcare business sector2 · Sep 2016 to Sep 2017

KPI25 concepts · 384 facts · Mar 2017 to Mar 2026

  • Adjustments128 · Mar 2021 to Mar 2026
  • Changes in other assets and liabilities328 · Mar 2021 to Mar 2026
  • Changes in provisions328 · Mar 2021 to Mar 2026
  • Changes in working capital128 · Mar 2021 to Mar 2026
  • Income tax228 · Mar 2021 to Mar 2026
  • of which: changes in inventories328 · Mar 2021 to Mar 2026
  • of which: changes in trade accounts receivable328 · Mar 2021 to Mar 2026
  • Operating result (EBIT)¹27 · Mar 2021 to Mar 2026
  • Other non-cash income and expenses327 · Mar 2021 to Mar 2026
  • of which: changes in trade accounts payable/refund liabilities325 · Mar 2021 to Mar 2026
  • Financial result222 · Mar 2021 to Mar 2026
  • EBITDA pre¹21 · Sep 2021 to Mar 2026
  • Neutralization of gains/losses on disposals of fixed assets and other disposals310 · Mar 2021 to Mar 2026
  • EBITDA²9 · Mar 2021 to Mar 2026
  • Gross Profit7 · Mar 2017 to Mar 2022
  • Adjustments (total)¹5 · Mar 2021 to Sep 2022
  • EBITDA pre margin (in % of net sales)²5 · Jun 2021 to Jun 2024
  • Gains (+) /losses (–) on the divestment of businesses5 · Mar 2021 to Sep 2022
  • Integration expenses/IT expenses5 · Mar 2021 to Sep 2022
  • Other adjustments5 · Mar 2021 to Sep 2022
  • Restructuring expenses5 · Mar 2021 to Sep 2022
  • Group research spending ratio4 · Mar 2017 to Mar 2022
  • Equity ratio3 · Dec 2023 to Dec 2025
  • Acquisition-related adjustments2 · Mar 2021 to Sep 2022

APM18 concepts · 63 facts · Mar 2016 to Mar 2026

  • Business free cash flow9 · Mar 2016 to Jun 2019
  • Integration  costs/IT costs6 · Jun 2016 to Jun 2018
  • Restructuring costs6 · Jun 2016 to Jun 2018
  • Acquisition-related exceptionals5 · Jun 2016 to Jun 2018
  • EBITDA pre exceptionals¹4 · Jun 2017 to Jun 2018
  • Exceptionals before impairment losses /reversals of impairment losses¹4 · Jun 2017 to Jun 2018
  • Gains / losses on the divestment of businesses4 · Jun 2016 to Jun 2017
  • Investments in property, plant and equipment, software as well as advance payments for intangible assets4 · Jun 2017 to Jun 2019
  • Other exceptionals4 · Jun 2017 to Jun 2018
  • Changes in trade accounts receivable and receivables from royalties and licenses as reported in the consolidated balance sheet3 · Jun 2018 to Mar 2019
  • Adjustment first-time consolidation of Sigma-Aldrich2 · Jun 2016
  • Adjustments in EBITDA2 · Mar 2024 to Mar 2026
  • Changes in inventories as reported in the consolidated balance sheet2 · Jun 2018 to Mar 2019
  • EBITDA²2 · Jun 2018
  • Exceptionals (total)¹2 · Jun 2017
  • Impairment losses2 · Jun 2018
  • Adjustments first-time consolidation of Sigma-Aldrich1 · Sep 2016
  • Lease payments31 · Mar 2019

Segments

683 facts

Figures broken down by business line, region, product or another axis the company reports on.

Business segment5 members · 681 facts

  • Healthcare233 · Mar 2016 to Jun 2026
  • Life Science220 · Mar 2016 to Jun 2026
  • Corporate and Other112 · Mar 2016 to Jun 2026
  • Performance Materials69 · Mar 2016 to Sep 2020
  • Electronics47 · Mar 2021 to Jun 2026

Region1 member · 2 facts

  • Europe2 · Sep 2016 to Mar 2017

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

32 calls · May 2018 to Aug 2026

Transcripts with management claims and analyst questions, one per fiscal period.

  • FY2026 Q22026-08-06
  • FY2026 Q12026-05-13
  • FY2025 Q42026-03-05
  • FY2025 Q32025-11-14
  • FY2025 Q22025-08-07
  • FY2025 Q12025-05-15
  • FY2024 Q42025-03-06
  • FY2024 Q32024-11-14
  • FY2024 Q22024-08-01
  • FY2024 Q12024-05-15
  • FY2023 Q42024-03-07
  • FY2023 Q32023-11-09
  • FY2023 Q22023-08-03
  • FY2023 Q12023-05-11
  • FY2022 Q42023-03-02
  • FY2022 Q32022-11-10

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of MERCK Kommanditgesellschaft auf Aktien (MRK) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 20, 2026) and refreshed every few hours.

MERCK Kommanditgesellschaft auf Aktien (MRK): FY2025 revenue €21.1B · FactIQ